We are live on ! Find out more
AVA

Atlas Venture Advisors Portfolio holdings

AUM $122M
1-Year Est. Return 26.28%
This Fund
S&P 500
This Quarter Est. Return
+28.95%
1 Year Est. Return
-26.28%
3 Year Est. Return
-22.79%
5 Year Est. Return
-46.44%
10 Year Est. Return
–
AUM
$590M
AUM Growth
+$126M
Cap. Flow
-$5.33M
Cap. Flow %
-0.9%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$5.33M
2
IAS
Integral Ad Science
IAS
+$17

Sector Composition

Rank Sector Weight
1 Communication Services 70.34%
2 Consumer Discretionary 29.51%
3 Healthcare 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IAS
1
DELISTED
Integral Ad Science
IAS
$409M 69.22%
22,722,770
-1
-0% -$17
DKNG icon
2
DraftKings
DKNG
$11.4B
$174M 29.51%
6,555,608
– –
ROKU icon
3
Roku
ROKU
$21.1B
$3.69M 0.63%
57,707
– –
SNAP icon
4
Snap
SNAP
$7.32B
$2.91M 0.49%
245,559
– –
LRMR icon
5
Larimar Therapeutics
LRMR
$416M
$915K 0.15%
292,184
– –
VRDN icon
6
Viridian Therapeutics
VRDN
$2.13B
– –
-209,505
Closed -$5.33M

Similar funds

RCWM
Red Crane Wealth Management San Francisco, California $122M AUM 14.77% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SO
Sierra Ocean Ripon, California $122M AUM 16.19% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Atlas Venture Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Atlas Venture Advisors held 6 positions worth $590M, up 27% from $464M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Advisors's Q2 2023 filing shows 1 reduced and 1 closed positions. The largest sale was Viridian Therapeutics, an estimated $5.33M.

By sector, the portfolio is most concentrated in Communication Services at 70% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Atlas Venture Advisors's biggest Q2 2023 reduction was Integral Ad Science, cutting an estimated $17.
  • Atlas Venture Advisors fully exited Viridian Therapeutics in Q2 2023, selling an estimated $5.33M.
  • Atlas Venture Advisors's ten largest holdings make up 100% of its $590M portfolio in Q2 2023.
  • Atlas Venture Advisors opened 0 new positions and closed 1 in Q2 2023.
  • Atlas Venture Advisors's portfolio value rose 27% quarter-over-quarter to $590M.

Based on Atlas Venture Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.